Jump to content

Difemetorex

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 17:33, 19 October 2020 (top: Task 17: replace to-be-deprecated: |name-list-format= (2× replaced; usage: 2 of 2); empty parameters removed;). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Difemetorex
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • Withdrawn
Identifiers
  • 2-[2-(diphenylmethyl)piperidin-1-yl]ethanol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H25NO
Molar mass295.426 g·mol−1
3D model (JSmol)
  • OCCN1C(CCCC1)C(c2ccccc2)c3ccccc3

Difemetorex (INN; sold as Cleofil), also known as diphemethoxidine, is a stimulant drug of the piperidine class which was used as an appetite suppressant, but produced intolerable side effects such as insomnia which limited its clinical use.[1][2][3][4][5] It was introduced in France by Ciba-Geigy in 1966 but is now no longer marketed.[6]

See also

References

  1. ^ Isbell H, Chrusciel TS. Dependence Liability of Non-Narcotic Drugs. Bulletin of the World Health Organization 1970; 43: Supplement.
  2. ^ Stepanek J, Zolliker VR (June 1971). "[Circulatory effects of the anorectic Diphemethoxidine compared with the effects of Amphetamine and Aminorex]". Archives Internationales de Pharmacodynamie et de Therapie. 191 (2): 376–99. PMID 5089225.
  3. ^ Stepanek J (September 1972). "[Alteration of the acid-base equilibrium by the anorectic diphemethoxidine in comparison with the effect of amphetamine and aminorex]". Archives Internationales de Pharmacodynamie et de Therapie. 199 (1): 122–38. PMID 5072180.
  4. ^ Hall JA, Morton I (1999). Concise dictionary of pharmacological agents: properties and synonyms. Kluwer Academic. ISBN 0-7514-0499-3.
  5. ^ "The use of common stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). Retrieved 2010-03-23.[permanent dead link]
  6. ^ Brudon P (1983). Médicaments pour tous en l'an 2000?: les multinationales pharmaceutiques suisses face au tiers monde : l'exemple du Mexique. France: Editions d'En bas. p. 207. ISBN 2-8290-0039-0.